Xtant posts $24.3 million in revenue, withdraws 2026 outlook amid strategic review
Key Facts
Xtant Medical reported on Nov. 16 results for the third quarter ended Sept. 30, disclosing revenue of $24.3 million as its board began an active review of strategic, operational and financial alternatives. The company said revenue fell from $33.3 million in the same quarter of 2025, but rose 5% from the second quarter of 2026, when it recorded $23.0 million. It attributed the year-over-year decline mainly to the absence of revenue from businesses it sold and wound-care licensing revenue that did not recur. The review comes alongside a decline in annual revenue and the withdrawal of its financial outlook for the year. The company said its results missed guidance for the second consecutive quarter.
Despite the year-over-year decline in total revenue, the biologics segment grew, with third-quarter revenue of $19.3 million, up 13% from the same period in 2025 and 11% from the second quarter of 2026. That revenue included $2.2 million in HEMOBLAST sales. The performance shows a divergence between growth in biologics and a decline in total revenue, which was affected by the absence of revenue from sold businesses and licensing. In August, Xtant announced an exclusive distribution agreement with Dilon, granting it U.S. commercial rights to HEMOBLAST and a U.S. sales team of about 20 people to support its biologics portfolio. The inclusion of the product’s sales in third-quarter results places the activity at the heart of the revenue mix for the period.
Gross margin fell to 56.3% in the third quarter from 66.1% a year earlier, the company said. Xtant attributed the decline mainly to a 670-basis-point impact from the discontinuation of high-margin wound-care licensing revenue and a 360-basis-point impact from sales mix. This followed a gross margin of 57.9% in the second quarter of 2026, compared with 68.6% in the same quarter of 2025. The company had linked the second-quarter margin decline to the loss of high-margin licensing revenue, lower production efficiency and increased reserves for excess and obsolete inventory. The comparison shows that year-over-year margin pressure continued in the third quarter, with the company citing licensing and sales mix among the reasons for the latest decline.
The board chairman said the company’s results missed guidance for the second consecutive quarter, adding: "This is unacceptable." He set the board’s priorities as improving execution and financial performance and maximizing shareholder value through the review. Alternatives under consideration include initiatives to improve operations and performance, capital allocation and structure options, and commercial or strategic partnerships. They also include restructuring, financing, acquisitions, divestitures, business combinations or other transactions. The board has not set a timeline for completing the review, and the statement said the review does not guarantee any particular outcome. The company is not providing revised annual guidance during the process.
Xtant withdrew its previous fiscal 2026 revenue outlook, saying it no longer expects to achieve it, and will not issue revised annual guidance while the review is underway. In its second-quarter results announcement, the company had lowered its range to between $99 million and $103 million, from $101 million to $105 million previously, citing biologics revenue below expectations and pressure on its amnion product line tied to the advanced wound-care market. In the second quarter, the company recorded a net loss of $9.4 million, compared with net income of $3.6 million in the same period of 2025. For the third quarter, XTNT shares closed at $0.2717 on Nov. 13, according to EL7 data. The statement provides no timeline for ending the review, while the list of announced alternatives spans partnerships, transactions, financing and restructuring.